What the research says about SS-31 (elamipretide)

What SS-31 is

SS-31 is a small, water-soluble, aromatic-cationic tetrapeptide that is taken up selectively by mitochondria, where it associates with cardiolipin, a phospholipid unique to the inner mitochondrial membrane. By binding cardiolipin it is described as stabilizing the folded cristae structure of mitochondria, reducing reactive-oxygen-species production, and supporting ATP generation ^[1]. In clinical development it is called elamipretide (and earlier MTP-131 or Bendavia) ^[1].

Because mitochondrial dysfunction is implicated in many conditions, SS-31 has been studied broadly, from heart failure to neurodegeneration to eye disease. Only one narrow use has reached regulatory approval. Material sold by research-chemical vendors is not the approved pharmaceutical product and is offered for laboratory and research use only.

What the human research has measured

The most rigorous human test was MMPOWER-3, a pivotal phase 3, randomized, double-blind, placebo-controlled trial of subcutaneous elamipretide in adults with genetically confirmed primary mitochondrial myopathy, with change in six-minute walk distance among the primary efficacy endpoints ^[3]. As reported, the trial did not demonstrate a significant benefit across the genotypically diverse study population ^[4]. A prespecified subgroup with disease-causing nuclear-DNA variants did show improvement on the six-minute walk test, while the subgroup with mitochondrial-DNA variants showed no difference from placebo, prompting genotype-specific post-hoc analyses to identify who might respond ^[4].

The other controlled human program is in Barth syndrome, a rare X-linked disorder featuring cardiomyopathy and skeletal-muscle weakness ^[6]. The TAZPOWER trial was a 28-week randomized, double-blind, placebo-controlled study followed by a long open-label extension in which patients continued elamipretide; ten patients entered the extension and eight reached the final visit, with muscle strength, walking distance, fatigue, echocardiographic measures, and cardiolipin biomarkers tracked over time ^[5]. On the strength of this program, elamipretide received accelerated approval in the USA in September 2025 to improve muscle strength in Barth syndrome patients meeting a weight threshold, the first disease-specific treatment approved for that condition ^[2].

Elamipretide remains in phase 3 development for dry age-related macular degeneration and mitochondrial myopathies ^[2]. Outside these programs, the evidence is largely preclinical and mechanistic.

What the preclinical work has measured

A large body of animal and cell research explores the cardiolipin-stabilizing mechanism. In aged mouse hearts, SS-31 partially reversed an age-related decline in diastolic function, and combining it with the NAD+ precursor NMN produced broader metabolic effects ^[9]. In a mouse model of inflammation-induced memory impairment, elamipretide was studied for effects on hippocampal mitochondrial function, oxidative stress, and cognition ^[8]. Reviews summarize similarly promising preclinical signals in kidney disease and heart failure ^[7].

These are findings in animals and cells. They motivate the human trials but do not themselves establish clinical benefit, and the human trials to date have given mixed results ^[3][4].

What the trials report on safety and adverse events

The controlled trials evaluated safety alongside efficacy. In the Barth-syndrome open-label extension, where the primary endpoints were safety and tolerability, elamipretide was reported to be well tolerated across the extended dosing period in the small group of patients followed ^[5]. MMPOWER-3 was designed to evaluate both efficacy and safety of the peptide given subcutaneously ^[3].

Because the approved indication is an ultra-rare disease studied in very small numbers, and because the largest trial missed its primary endpoint, the controlled human safety database is limited in size. None of this is a safety guarantee or a prediction for any individual, and it says nothing about use outside the studied populations. Material sold by research-chemical vendors is not the approved product and has not passed an equivalent safety evaluation. This is not medical advice; consult a qualified professional and read the studies directly.

How strong is the evidence

The evidence base is characterized as moderate. SS-31/elamipretide has genuine randomized, placebo-controlled human trials and a narrow regulatory approval, which sets it apart from purely preclinical peptides ^[2][3][5]. What tempers that is the content of the results: the pivotal mitochondrial-myopathy trial did not meet its primary endpoints, the Barth-syndrome evidence rests on very small numbers, and most other applications remain preclinical ^[3][4][9]. "Moderate" describes the quality and design of the available human trials, not a verdict that the compound works for any general purpose.

Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.